Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | SCN4A | P35499 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19262548 | 1.00 | MAPK1 (0.38) | MAPK1KDM4ETDP1AOC3TSHR | |
| SCHEMBL20332600 | 0.90 | HIF1A (0.39) | MAPK1TSHRHIF1A | |
| SCHEMBL18550905 | 0.88 | AOC3 (0.39) | MAPK1AOC3TSHRHIF1A | |
| SCHEMBL13881750 | 0.86 | TSHR (0.38) | MAPK1KDM4EAOC3TSHRHIF1A | |
| SCHEMBL2206399 | 0.86 | TSHR (0.38) | MAPK1KDM4EAOC3TSHRHIF1A | |
| SCHEMBL29818647 | 0.86 | TSHR (0.38) | MAPK1KDM4EAOC3TSHRHIF1A | |
| SCHEMBL19291709 | 0.86 | TSHR (0.38) | MAPK1KDM4EAOC3TSHRHIF1A | |
| SCHEMBL20295212 | 0.86 | TSHR (0.38) | MAPK1KDM4EAOC3TSHRHIF1A | |
| SCHEMBL18539795 | 0.83 | TSHR (0.41) | MAPK1KDM4EAOC3TSHRHIF1A | |
| SCHEMBL4568792 | 0.82 | TSHR (0.40) | MAPK1KDM4EAOC3TSHRHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12029708-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-10639286-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2020-05-05 | — | — | US | disclosed |
| US-20190183816-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. | 2019-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12029708-B2 | Alkoxy compounds for disease treatment | ALDH1A2, CLN6, AGER | MAPK1 2505/4885KDM4E 2349/4885TDP1 499/4885 |
| US-20190183816-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ALDH1A2, CLN6, AGER | MAPK1 2505/4885KDM4E 2349/4885TDP1 499/4885 |
| US-10639286-B2 | Alkoxy compounds for disease treatment | ALDH1A2, CLN6, AGER | MAPK1 2505/4885KDM4E 2349/4885TDP1 499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.